$0.42
-0.02 (-5.41%)
Open$0.47
Previous Close$0.44
Day High$0.47
Day Low$0.41
52W High$1.49
52W Low$0.41
Volume—
Avg Volume104.2K
Market Cap6.10M
P/E Ratio—
EPS$-0.70
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+8,564.1% upside
Current
$0.42
$0.42
Target
$36.06
$36.06
$23.45
$36.06 avg
$38.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 640.4K | 1.10M | 1.13M |
| Net Income | -28,238,437 | 89.2K | 117.7K |
| Profit Margin | -4,409.1% | 8.1% | 10.4% |
| EBITDA | -29,611,596 | 177.4K | 182.1K |
| Free Cash Flow | — | 70.9K | 72.7K |
| Rev Growth | — | +5.3% | -7.0% |
| Debt/Equity | — | 0.17 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |